Press Releases iX Biopharma Ltd.

Equities

42C

SG1BD9000009

Market Closed - Singapore S.E. Other stock markets 09:47:51 10/05/2024 BST			5-day change	1st Jan Change
0.039 ^SGD	-2.50%		-17.02%	-13.33%

03-12	Singaporean Shares End Marginally Higher; Biopharma's Shares Climb 2% on Introduction of New Sublingual Wafer	MT
03-12	IX Biopharma Introduces New Sublingual Wafer	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IX Biopharma : Sustainability Report	19/09/22	PU
General Announcement::CHANGES IN THE COMPOSITION OF THE BOARD AND BOARD COMMITTEES	27/10/21	PU
General Announcement::Minutes of Annual General Meeting held on 15 October 2021	26/10/21	PU
General Announcement::iX Biopharma Expands Nutraceuticals Portfolio With Innovative Anti-Aging Sublingual NAD+ Product	26/10/21	PU
General Announcement::iX Biopharma Signs Wafesil Licensing Agreement with China Resources Pharmaceutical Commercial Group	30/09/21	PU
IX Biopharma : 2H (Unaudited)	22/08/21	PU
Employee Stock Option/ Share Scheme::GRANT OF SHARE OPTION PURSUANT TO iX EMPLOYEE SHARE OPTION SCHEME	16/07/21	PU
IX Biopharma : The Board of Directors refers to the announcement dated 30 June 2021 in relation to, amongst others, the lodgement of the offer information statement in connection with the proposed renounceable non-underwritten rights issues of up to 48,814,711 new ordinary shares in the capital of the Company ("Offer Information Statement").	01/07/21	PU
General Announcement::Press Release: iX Biopharma Commences Supply of Medicinal Cannabis Wafers to Brazil	28/06/21	PU
REPL::Rights::Voluntary	21/06/21	PU
IX Biopharma : is pleased to announce that it will supply its novel Wafermine sublingual ketamine wafers in a pilot study funded by Chris O’Brien Lifehouse, one of Australia’s leading comprehensive cancer hospitals in Camperdown, Sydney. The study will evaluate the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain.	15/06/21	PU
IX Biopharma : Expands Wafer Production Capacity to Meet Growing Demand	02/06/21	PU
IX Biopharma : is pleased to announce that the United States Food and Drug Administration (US FDA) has granted the Company an orphan drug designation for treatment of patients with Complex Regional Pain Syndrome (CRPS) with ketamine.	18/05/21	PU
IX Biopharma : enters cooperation deal with China Resources Pharmaceutical Commercial Group	07/04/21	AQ
IX Biopharma: Enters Strategic Cooperation Framework Agreement With China Resources Pharmaceutical Commercial Group.	07/04/21	AQ
IX Biopharma : is pleased to announce it has entered into a cooperation deal with China Resources Pharmaceutical Commercial Group.	07/04/21	PU
IX Biopharma : has reported its first half results for the financial year as of 31 December 2020.	15/02/21	PU
IX Biopharma : receives positive EMA Scientific Advice for Wafermine	11/11/20	AQ
IX Biopharma : is pleased to announce that it has received positive feedback from the European Medicines Agency (EMA) in its scientific advice to the Company regarding its Phase 3 clinical development programme for Wafermine, its sublingual ketamine wafer, for registration in Europe.	10/11/20	PU
IX Biopharma : obtains approval and registration of Silcap for the treatment of male erectile dysfunction in Singapore	21/10/20	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases iX Biopharma Ltd.

Equities

42C

SG1BD9000009

Press Releases

Filters